{"filings":[{"id":1224518,"accession_number":"0001193125-26-279776","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2026-06-23T21:15:09+00:00","items":["8.01"],"status":"ready","headline":"FTC grants early termination of HSR waiting period for Catalyst-Angelini merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["FTC early termination of HSR Act waiting period granted June 16; Catalyst aware June 22.","Closing still requires majority shareholder approval and other customary conditions.","Parties expect deal to close in Q3 2026.","Catalyst shareholders to vote on merger as detailed in definitive proxy statement filed June 8."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":14002,"accession_number":"0001193125-26-216929","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2026-05-11T20:33:41+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst Q1 2026 revenue $149.4M; FIRDAPSE up 18%, AGAMREE up 67% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue net $149.3M for Q1 2026, up 5.6% YoY from $141.4M.","FIRDAPSE net revenue $98.9M (+18% YoY); AGAMREE $36.7M (+67%); FYCOMPA $13.8M (-61%).","GAAP net income $63.7M ($0.52 basic EPS); non-GAAP net income $100.3M ($0.82 basic EPS).","Cash & equivalents $755.9M at March 31, 2026, up from $709.2M; no funded debt.","No forward guidance or updated FY2026 outlook provided in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":149390000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92455,"accession_number":"0001193125-26-210518","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["1.01","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Angelini Pharma to acquire Catalyst Pharma for $4.1B ($31.50/share), premium 28% to VWAP","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All outstanding shares acquired for $31.50 cash per share; total equity value ~$4.1B (21% premium to unaffected close).","Transaction expected to close Q3 2026, subject to stockholder vote and HSR antitrust clearance.","Termination fee of ~$155.5M payable by Catalyst under certain conditions; no financing condition.","Patent litigation with Hetero on FIRDAPSE generic settled; Hetero cannot market before Jan 2035 if approved.","Directors and executive officers entered voting agreements to support the merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103302,"accession_number":"0001193125-26-114764","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K/A","filed_at":"2026-03-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Catalyst Pharma patent trial delayed to May 18, 2026 in NJ district court","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["District Court of NJ delayed bench trial between Catalyst and Hetero USA from Mar 23 to May 18, 2026.","Trial concerns validity of Orange Book-listed patents for FIRDAPSE expiring in 2032, 2034, and 2037.","The trial is a bench trial (judge only) and will be held in the District of New Jersey."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103305,"accession_number":"0001193125-26-114306","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Catalyst bench trial for FIRDAPSE patents delayed from March 23 to May 18, 2026","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["District of New Jersey order delays start of bench trial to May 18, 2026, originally March 23, 2026.","Trial concerns validity of Orange Book-listed patents for FIRDAPSE expiring 2032, 2034, and 2037.","Litigation is with Hetero USA, Inc. over Catalyst's proprietary drug FIRDAPSE patents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103304,"accession_number":"0001193125-26-071702","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst reports record FY2025 revenue $589M (+20% YoY); FY2026 guidance $615-645M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2025 total revenues $589.0M, up 19.8% YoY; GAAP diluted EPS $1.68 vs $1.31.","Q4 2025 total revenues $152.6M; FIRDAPSE revenue grew 18.3% in Q4; AGAMREE grew 67.5%.","FY2026 revenue guidance $615M-$645M; promoted product revenue expected to grow 20%+.","Non-GAAP net income $346.2M for FY2025 vs $276.3M, up 25.3%.","Cash and equivalents $709.2M as of Dec 31, 2025, up 37% YoY."],"consensus_eps_estimate":0.3427,"consensus_eps_actual":1.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":588989000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103303,"accession_number":"0001193125-26-009822","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Catalyst presents at JPMorgan; exhibit lacks substantive details","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation at 44th Annual JPMorgan Healthcare Conference on January 12, 2026.","Filed exhibit (99.1) contains only title slide and safe harbor; no financial or strategic updates provided.","No new guidance, product milestones, or material events disclosed in the available filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119555,"accession_number":"0001193125-25-267038","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst Pharma Q3 rev $148.4M (+17% YoY); raises FY25 revenue guidance to $565-$585M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $52.8M ($0.42 diluted EPS); non-GAAP net income $86.1M ($0.68 diluted EPS).","FIRDAPSE net revenue $92.2M (+16.2% YoY); AGAMREE net revenue $32.4M (+115.2% YoY).","FYCOMPA net revenue $23.8M (-25.8% YoY) as first generic tablet entered market in Q2 2025.","Cash and equivalents $689.9M as of Sep 30, 2025; $200M share repurchase program announced.","Full-year AGAMREE guidance raised to $105-$115M; FYCOMPA guidance raised to $100-$110M."],"consensus_eps_estimate":0.3386,"consensus_eps_actual":1.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":436376000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119554,"accession_number":"0001193125-25-226837","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst Pharma announces $200M share repurchase program through Dec 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $200M share repurchase from Oct 1, 2025 to Dec 31, 2026.","Company had >$650M cash & equivalents and no funded debt as of June 30, 2025.","Repurchases may be via open market or privately negotiated; timing depends on stock price and conditions.","Program may be suspended or terminated anytime; no obligation to buy any specific amount.","Company plans to use existing cash on hand to fund the repurchase program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136121,"accession_number":"0001193125-25-191273","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K/A","filed_at":"2025-08-28T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Catalyst settles FIRDAPSE patent suit with Lupin; generic entry delayed to Feb 2035","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Lupin receives license to market generic FIRDAPSE no earlier than February 25, 2035, if FDA-approved.","All pending patent litigation between Catalyst/SERB and Lupin will be terminated.","Previous settlements reached with Teva Pharmaceuticals and Inventia Healthcare Limited.","Ongoing FIRDAPSE patent litigation against Hetero remains active.","Confidential settlement agreement to be submitted to FTC and DOJ for review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136125,"accession_number":"0001193125-25-187733","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst settles Lupin patent litigation; generic FIRDAPSE launch no earlier than Feb 2035","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Lupin granted license to market generic FIRDAPSE beginning February 25, 2035, if FDA-approved.","All ongoing patent litigation between Catalyst/SERB and Lupin in New Jersey terminated.","Prior settlements with Teva and Inventia for FIRDAPSE generics already in place.","Pending patent litigation against Hetero for FIRDAPSE's Orange Book-listed patents continues.","Settlement will be submitted to FTC and DOJ for review as required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136124,"accession_number":"0001193125-25-175477","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NCCN SCLC guidelines add LEMS testing and amifampridine (FIRDAPSE) treatment recommendation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NCCN guidelines for SCLC updated to recommend VGCC antibody testing for LEMS diagnosis.","Amifampridine (FIRDAPSE) added as a supportive care treatment option for LEMS in SCLC.","Approximately 50% of LEMS cases are cancer-associated, most commonly with SCLC.","Catalyst internal analysis suggests 90% of LEMS in SCLC patients may be undiagnosed.","Guideline inclusion could increase clinical awareness and drive adoption of VGCC testing and amifampridine use."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136123,"accession_number":"0001193125-25-174540","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst Pharma reports Q2 2025 revenue of $146.6M (+19.4% YoY); GAAP net income $52.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FIRDAPSE Q2 net revenue $84.8M (+9.7% YoY); first-half 2025 net revenue $168.6M (+16.9% YoY).","AGAMREE Q2 net revenue $27.4M (+212.9% YoY); first-half net revenue $49.4M (+398.0% YoY).","FYCOMPA Q2 net revenue $34.3M (-6.0% YoY due to generic entry post LOE).","Non-GAAP diluted EPS $0.68, up from $0.56 in Q2 2024; cash $652.8M, no funded debt.","Reaffirmed FY2025 total revenue guidance of $545M to $565M."],"consensus_eps_estimate":0.3937,"consensus_eps_actual":0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":287984000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136122,"accession_number":"0001193125-25-172653","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Catalyst expands Board to 7 with appointment of Dr. Daniel Curran","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 6 to 7 members; Dr. Curran appointed effective immediately.","Curran brings 25+ years pharma experience; served as SVP at Takeda Rare Genetics (2019-2023).","Currently CEO of Timberlyne Therapeutics and Managing Partner at Mountainfield Venture Partners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153179,"accession_number":"0001193125-25-133348","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst Pharma appoints Dr. William Andrews as CMO; Dr. Ingenito retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gary Ingenito retired as Chief Medical and Regulatory Officer effective June 1, 2025; no disagreement with management.","William Andrews appointed as new Chief Medical Officer effective June 2, 2025, reporting to CEO Richard Daly.","Andrews brings 24 years of biopharma experience, including CMO roles at Flexion, Akcea, and Acer Therapeutics.","Ingenito will serve as a consultant to assist with the transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153178,"accession_number":"0001193125-25-125872","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Catalyst Pharmaceuticals announces board election results and director O'Keeffe retirement at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Richard J. Daly, McEnany, Denkhaus, Harper, Thompson, Tierney elected to board; O'Keeffe retired after 20+ years, no disagreement.","Shareholders approved amendment to 2018 Stock Incentive Plan (85.4M for, 4.0M against).","Advisory vote on 2024 executive compensation passed (82.7M for, 6.5M against).","Grant Thornton LLP ratified as independent auditor for FY2025 (99.9M for, 1.2M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153177,"accession_number":"0001193125-25-114926","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst Q1 revenues $141.4M (+43.6% YoY); GAAP EPS $0.45; reaffirms FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total product revenue $141.4M, up 43.6% YoY; FIRDAPSE $83.7M (+25.3%), AGAMREE $22.0M (from $1.2M).","GAAP net income $56.7M ($0.45 diluted EPS); Non-GAAP net income $86.6M ($0.68 diluted EPS).","Cash and equivalents $580.7M as of March 31, 2025; no debt.","Reaffirms full-year 2025 total revenue guidance of $545M–$565M.","AGAMREE commercial launch momentum with 1,777.5% YoY revenue growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":141421000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153176,"accession_number":"0001193125-25-076358","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst Pharmaceuticals: Health Canada accepts AGAMREE NDS with Priority Review for DMD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Health Canada accepted New Drug Submission for AGAMREE (corticosteroid) for Duchenne muscular dystrophy.","Submission granted Priority Review; potential marketing authorization before end of 2025.","If approved, AGAMREE would be first and only DMD treatment indicated in Canada.","AGAMREE already FDA-approved (Oct 2023) and commercially available in the U.S. since March 2024.","Sub-licensee Kye Pharmaceuticals markets FIRDAPSE in Canada for LEMS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171955,"accession_number":"0001193125-25-036816","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst Pharma reports FY2024 revenue $491.7M (+23.5% YoY), guides FY2025 $545-565M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net product revenue $141.8M; full-year FIRDAPSE revenue $306M (+18.4%), AGAMREE $46M (new launch).","GAAP net income $163.9M ($1.31 diluted EPS) vs $71.4M ($0.63) in 2023; non-GAAP net income $276.3M ($2.21 diluted EPS).","Cash and equivalents $517.6M at year-end, up 276% from $137.6M a year ago.","Full year 2025 revenue guidance set at $545-565M, reflecting continued growth momentum."],"consensus_eps_estimate":null,"consensus_eps_actual":1.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":491734000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171954,"accession_number":"0001193125-25-012233","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Catalyst Pharma director O'Keeffe to retire; not standing for reelection at 2025 meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Charles B. O'Keeffe, 85, will not stand for reelection at the 2025 annual meeting; term ends at that meeting.","O'Keeffe has served as independent director since 2004, currently Lead Independent Director.","Retirement not due to any disagreement with company on operations, policies, or practices.","Corporate Governance Committee will hire a recruitment firm to search for a replacement director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171953,"accession_number":"0001193125-25-009573","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst sub-licensee DyDo launches FIRDAPSE in Japan for LEMS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DyDo Pharma launched FIRDAPSE (amifampridine) 10 mg tablets in Japan for Lambert-Eaton myasthenic syndrome (LEMS).","FIRDAPSE is the only U.S. FDA-approved therapy for LEMS in adults and pediatric patients 6 years and older.","Previously approved in U.S., Europe, and Canada; Japan launch expands geographic footprint.","Catalyst CEO Richard Daly cited commitment to health equity and increasing patient access worldwide."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171952,"accession_number":"0001193125-25-004908","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Catalyst Pharmaceuticals posts corporate presentation for J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On January 13, 2025, Catalyst Pharmaceuticals posted a corporate presentation to its website.","The presentation may be used in discussions with investors, analysts, and other parties.","The presentation is attached as Exhibit 99.1 to the 8-K filing.","Catalyst Pharmaceuticals (ticker: CPRX) presented at the J.P. Morgan Healthcare Conference in January 2025.","The filing includes forward-looking statements with risks described in the company's annual report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171951,"accession_number":"0001193125-25-003549","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst settles FIRDAPSE patent suit with Teva; generic entry barred until Feb 2035","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Teva agrees not to market generic FIRDAPSE in the U.S. before February 25, 2035, if FDA approved.","All ongoing FIRDAPSE patent litigation between Catalyst/SERB and Teva will be terminated.","Litigation against remaining defendants Hetero (all patents) and Lupin (2037 patent) is ongoing.","Confidential license agreement to be submitted to FTC and DOJ for review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188952,"accession_number":"0001193125-24-252194","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst Pharma Q3 revenue $128.7M (+25% YoY); GAAP EPS $0.35; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $128.7M, up 25.3% YoY; GAAP net income $43.9M ($0.35 diluted).","Non-GAAP net income $71.1M ($0.57 diluted); cash and equivalents $442.3M.","FIRDAPSE net rev $79.3M (+19.7%); AGAMREE early launch $15.0M; FYCOMPA $32.1M.","Full-year 2024 total revenue guidance raised to $475-485M.","Q3 2023 GAAP net loss of $30.8M vs. current net income of $43.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":349914000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205426,"accession_number":"0001193125-24-226538","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst earns $2.1M milestone as Japan approves FIRDAPSE for LEMS","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Japan's Ministry of Health approved DyDo's NDA for FIRDAPSE (amifampridine) 10 mg to treat Lambert-Eaton myasthenic syndrome (LEMS).","Catalyst receives JPY 300 million (~$2.1M) milestone payment from sub-licensee DyDo upon approval.","FIRDAPSE is the only FDA-approved LEMS treatment in the U.S.; approval expands access to Japan.","Catalyst CEO says approval underscores commitment to expanding rare disease product portfolio beyond the U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205425,"accession_number":"0001193125-24-195950","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst Q2 revenue $122.7M (+23% YoY); GAAP EPS $0.33, non-GAAP $0.56; guides upper end of $455-475M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q2 2024 revenue $122.7M, up 23.3% YoY; FIRDAPSE $77.4M (+19.2%), FYCOMPA $36.5M (+5.7%), AGAMREE $8.7M (new launch).","GAAP net income $40.8M ($0.33 diluted); non-GAAP net income $69.6M ($0.56 diluted), up 15.3% YoY.","Cash and equivalents $375.7M at June 30, 2024, up from $137.6M at Dec 31, 2023 (+173%).","Reaffirms 2024 total revenue guidance of $455-$475M; expects results in upper half of range.","Announced license agreement for AGAMREE in Canada to expand rare orphan portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":221219000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205424,"accession_number":"0001193125-24-186261","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst grants Kye exclusive Canadian rights to AGAMREE for DMD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kye Pharmaceuticals gets exclusive Canadian rights to commercialize AGAMREE (vamorolone) for Duchenne Muscular Dystrophy.","Catalyst will supply product; Kye responsible for Health Canada approval and all commercialization in Canada.","Catalyst receives upfront payment, plus potential reimbursement, sales milestones, and royalties from Kye.","Kye already markets Catalyst's FIRDAPSE in Canada; AGAMREE application to Health Canada expected by early 2025.","Agreement expands AGAMREE's North American footprint beyond U.S. approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222336,"accession_number":"0001193125-24-150433","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves higher max daily dose of FIRDAPSE for LEMS to 100 mg","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved sNDA increasing FIRDAPSE max daily dose from 80 mg to 100 mg for adults and peds >45 kg with LEMS.","FIRDAPSE is the only U.S.-approved treatment for LEMS; expanded dosing offers greater treatment flexibility.","CEO Richard Daly states approval will have meaningful impact on LEMS patient outcomes.","Catalyst Pathways patient support program available for eligible patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222335,"accession_number":"0001193125-24-144049","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Catalyst Pharmaceuticals shareholders elect directors and approve incentive plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected: Daly, McEnany, Denkhaus, Harper, O'Keeffe, Thompson, Tierney.","Amendment to 2018 Stock Incentive Plan approved with 86.8M for, 2.9M against, 168k abstained.","Advisory vote on 2023 executive compensation passed: 84.2M for, 5.5M against, 182k abstained.","Ratification of Grant Thornton as independent auditor approved: 99.6M for, 2.0M against, 79k abstained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222334,"accession_number":"0001193125-24-134303","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst Q1 revenue $98.5M (+15.4% YoY); AGAMREE launch adds $1.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q1 2024 net product revenue $98.5M, up 15.4% YoY; FIRDAPSE net revenue $66.8M (+16.2%).","AGAMREE contributed $1.2M net revenue in first two weeks of U.S. launch, surpassing initial expectations.","GAAP net income $23.3M ($0.19 diluted EPS); Non-GAAP net income $46.8M ($0.38 diluted EPS).","Cash and cash equivalents $310.4M as of March 31, 2024, a 125.5% increase from year-end 2023.","Full-year 2024 total revenue guidance reaffirmed at $455M-$475M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":98509000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241864,"accession_number":"0001193125-24-066931","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst launches AGAMREE (vamorolone) in US for Duchenne Muscular Dystrophy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AGAMREE (vamorolone) oral suspension 40 mg/mL now commercially available by prescription for DMD patients aged 2+.","FDA approved Oct 26, 2023; launch follows approval with nationwide specialty pharmacy network.","Pivotal Phase 2b VISION-DMD study showed comparable efficacy with reduced bone health and growth side effects vs. standard corticosteroids.","Catalyst Pathways patient support program provides one-on-one education and financial assistance for eligible patients.","DMD affects ~11,000–13,000 US patients; ~70% currently on corticosteroid therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241863,"accession_number":"0001193125-24-051235","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst Pharma reports record 2023 revenue of $398.2M (+85.9% YoY); non-GAAP EPS $1.96","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 total revenue $110.6M (+82% YoY); full-year GAAP net income $71.4M ($0.63 diluted).","Non-GAAP net income $223.2M ($1.96 diluted) vs. $113.9M ($1.02) in 2022, up 96%.","FIRDAPSE net revenue $258.4M (+20.8%); FYCOMPA contributed $138.1M since acquisition.","AGAMREE FDA approval for Duchenne MD; commercial launch on track for Q1 2024.","FY2024 total revenue guidance $455M-$475M, implying ~14-19% growth vs. 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":398204000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241862,"accession_number":"0001193125-24-041520","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst announces VISION-DMD vamorolone study published in Neurology","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Peer-reviewed journal Neurology published Santhera's VISION-DMD study on vamorolone (AGAMREE) for DMD.","Study of 121 boys aged 4 to <7 years showed 6 mg/kg/d vamorolone maintained motor improvements to 48 weeks.","Vamorolone reversed prednisone-induced bone morbidities including stunted growth and bone biomarker decline.","Catalyst holds exclusive North American commercialization rights for AGAMREE, already approved in US.","Results support long-term efficacy and safety profile of vamorolone for Duchenne muscular dystrophy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241861,"accession_number":"0001193125-24-005292","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst Pharmaceuticals closes $150M public offering of 10M shares at $15; net proceeds ~$140.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 10,000,000 shares of common stock at $15.00 per share in an underwritten public offering.","Net proceeds after underwriting discounts and estimated expenses were approximately $140.1 million.","Underwriters granted a 30-day option to purchase up to an additional 1,500,000 shares.","Proceeds to be used for potential acquisition of new product candidates and general corporate purposes.","Bookrunners: BofA Securities, Citigroup, Piper Sandler, Cantor, Truist Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241860,"accession_number":"0001193125-24-003940","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Catalyst Pharmaceuticals posts corporate presentation; no new material financial or business updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed an 8-K on January 8, 2024, announcing a corporate presentation posted to its website for investor discussions.","Presentation cover page and safe harbor language provided; no specific financial results, pipeline updates, or material events included.","No earnings, M&A, leadership changes, debt, litigation, cyber, dividend, or regulatory actions reported in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241859,"accession_number":"0001193125-24-003489","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Catalyst Pharmaceuticals prices public offering of 10M shares at $15.00, raising $150M gross","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Offering of 10,000,000 shares at $15.00 each, gross proceeds $150M; net proceeds ~$140.1M.","Underwriters have 30-day option to purchase up to an additional 1.5M shares.","Net proceeds to fund potential acquisition of new product candidates and general corporate purposes.","Offering expected to close on January 9, 2024; underwriters include BofA Securities and Citigroup."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259305,"accession_number":"0001193125-23-298644","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2023-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst partner DyDo submits NDA in Japan for FIRDAPSE; milestone payment triggered","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["DyDo Pharma submitted NDA to PMDA for FIRDAPSE (amifampridine) 10 mg for LEMS in Japan.","Submission based on favorable interim data after six months of the safety-phase registration study.","Upon acceptance of NDA filing, Catalyst due JPY 200M (~$1.4M USD) milestone payment from DyDo.","Territorial rights automatically expand to Asia, Central/South America; plans underway for global partnerships.","PMDA review period expected to be a minimum of nine months from submission date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259304,"accession_number":"0001193125-23-290725","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Catalyst Pharma appoints Michael Kalb as CFO; Alicia Grande to retire at year-end 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alicia Grande to retire as CFO at end of 2023; will remain as consultant through Dec 31, 2024.","Michael W. Kalb appointed EVP & CFO effective Jan 1, 2024; base salary $525k, bonus up to 50%, equity grant $3M.","Dr. Steven Miller promoted to EVP, Chief Operating & Scientific Officer; Jeffrey Del Carmen to EVP, Chief Commercial Officer.","Kalb has 30+ years pharma/finance experience, previously CFO of Impel, CinCor, and Amarin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259303,"accession_number":"0001193125-23-273563","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst Q3 net revenues $102.7M (+79% YoY); non-GAAP EPS $0.49; raises FY revenue guidance to $390-395M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss per diluted share $(0.29) reflects $81.5M one-time IPR&D expense from AGAMREE license acquisition.","Non-GAAP net income $55.9M ($0.49 diluted), up 95% YoY; total net revenues increased 79% to $102.6M.","FDA approved AGAMREE (vamorolone) for Duchenne muscular dystrophy; commercial launch expected Q1 2024.","Raised full-year 2023 total revenue guidance to $390-$395M from prior $370-$380M.","sNDA for FIRDAPSE maximum daily dose increase to 100 mg accepted for filing by FDA; two new FIRDAPSE patents allowed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":287636000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259302,"accession_number":"0001193125-23-270432","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst Pharma receives two new US patent allowances for FIRDAPSE, extending IP protection to mid-2032","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO allowed two patents covering FIRDAPSE bioavailability under fasting/fed conditions; expected grant within two months.","Patents expire mid-2032; will be listed in FDA Orange Book, raising total listed patents to eight.","CEO states patent exclusivity in US until 2037; these new patents strengthen IP estate.","FIRDAPSE is only approved US treatment for Lambert-Eaton myasthenic syndrome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259301,"accession_number":"0001193125-23-265168","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst reports FDA approval of AGAMREE for DMD; expects Q1 2024 launch","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Santhera received FDA approval for AGAMREE (vamorolone) oral suspension 40 mg/mL for DMD in patients aged 2+.","Catalyst holds exclusive North American license; NDA transfer from Santhera to Catalyst is prompt.","Catalyst expects to commercially launch AGAMREE in Q1 2024 with a patient assistance program.","AGAMREE has orphan drug exclusivity (7 years) and patent protection potentially until 2040.","Approval based on Phase 2b VISION-DMD study and open-label extension data up to 48 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259300,"accession_number":"0001193125-23-259961","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2023-10-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Catalyst Pharmaceuticals appoints Richard J. Daly as CEO, effective Jan 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrick J. McEnany retires as CEO effective Dec 31, 2023, remains Chairman of the Board.","Richard J. Daly, Board member since 2015, named CEO; previously President at CARsgen, CEO of Neuralstem.","Daly receives base salary of $750,000, bonus up to 75% of base, stock options for 1,365,319 shares at $13.30.","Options and restricted stock units vest in 5 annual installments starting Jan 1, 2025.","Daly to become consultant from Dec 1, 2023 for transition with McEnany."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259299,"accession_number":"0001193125-23-255742","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2023-10-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts Catalyst's sNDA to increase FIRDAPSE max dose to 100 mg; PDUFA June 4, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted supplemental NDA to increase FIRDAPSE maximum daily dose from 80 mg to 100 mg for Lambert-Eaton myasthenic syndrome.","Prescription Drug User Fee Act action date set for June 4, 2024.","FIRDAPSE is currently approved for adults and children ages 6-17 with LEMS.","Chairman and CEO Patrick J. McEnany highlighted the milestone for addressing patient needs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276567,"accession_number":"0001193125-23-241475","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Catalyst Pharma presents at Cantor Healthcare Conference, slide deck furnished","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Chairman and CEO Patrick McEnany and senior management presenting at Cantor Global Healthcare Conference on September 26, 2023.","Webcast available on company website; replay for 14 days.","Slide deck attached as Exhibit 99.1; no new financial results or guidance disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276566,"accession_number":"0001193125-23-221544","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2023-08-25T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Catalyst Pharma elects seven directors at annual meeting; Philip Coelho retires from board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patrick J. McEnany, Richard J. Daly, Donald A. Denkhaus, Molly Harper, Charles B. O’Keeffe, Tamar Thompson, and David S. Tierney elected to board for 2024 term.","Philip H. Coelho, board member since 2002, did not stand for re-election; retirement not due to any disagreement.","Shareholders approved amendment to 2018 Stock Incentive Plan with 73.2M for, 2.7M against.","Advisory vote on named executive officer compensation passed with 72.6M for, 2.9M against.","Ratification of Grant Thornton as auditor for FY2023 approved with 87.6M for, 0.3M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276565,"accession_number":"0001193125-23-207423","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst Q2 revenue $99.6M, GAAP EPS $0.33 (vs $0.20), raises FY2023 guide to $380M-$390M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net product revenue $99.5M: FIRDAPSE $64.9M (+22% YoY); FYCOMPA $34.6M first-time contribution.","GAAP net income $37.8M, diluted EPS $0.33; Non-GAAP net income $60.4M, diluted EPS $0.53.","Raised FY2023 total revenue guidance to $380M-$390M.","Closed acquisition of North American vamorolone license for $75M in July; $15M Santhera equity investment and $10M Ruzurgi installment paid post-Q2.","Submitted sNDA for FIRDAPSE to increase maximum indicated dose to 100 mg/day."],"consensus_eps_estimate":null,"consensus_eps_actual":0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":184948000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276564,"accession_number":"0001193125-23-197742","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2023-07-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Catalyst CEO Patrick J. McEnany to retire by end of 2023; remains Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Patrick J. McEnany informed board of intention to retire as CEO by end of 2023.","McEnany will continue as non-executive Chairman of the Board after retirement.","Board has retained a nationally recognized executive recruitment firm to find successor.","McEnany stated retirement not due to any disagreement with management or board.","McEnany remains Catalyst's largest individual stockholder."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276563,"accession_number":"0001193125-23-191394","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2023-07-21T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"Catalyst completes $75M license for vamorolone, a DMD drug with PDUFA Oct 26, 2023","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-cash $75M license payment plus $15M equity investment for 11.26% stake in Santhera.","Vamorolone has FDA Fast Track and Orphan Drug status; PDUFA action date Oct 26, 2023.","Catalyst expects to launch vamorolone in the U.S. early Q1 2024, if approved.","Minimal sales force expansion (<10 new reps) due to synergy with existing neuromuscular franchise.","Catalyst will pay milestones and royalties on net sales; vamorolone rights cover U.S., Canada, Mexico."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294327,"accession_number":"0001193125-23-173863","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Catalyst Pharma licenses vamorolone rights for DMD from Santhera; $75M upfront + $15M investment","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Catalyst pays $75M upfront for exclusive North America license to vamorolone, a DMD drug under FDA review with PDUFA date Oct 26, 2023.","Catalyst also invests $15M in Santhera at CHF 0.9477 (~$1.08) per share for Phase IV and additional indication development.","If approved, Catalyst expects to launch vamorolone in U.S. early Q1 2024; Santhera may receive regulatory/sales milestones and royalties.","Transaction includes right of first negotiation for Europe and Japan if Santhera seeks partnerships; closing expected Q3 2023.","Vamorolone has FDA Fast Track and Orphan Drug designations; met primary endpoint in Phase 2b VISION-DMD study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294326,"accession_number":"0001193125-23-158979","cik":1369568,"company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","form_type":"8-K","filed_at":"2023-06-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst reaffirms FY2023 revenue $375M-$385M; non-GAAP net income $195M-$205M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirms full-year 2023 total revenue guidance of $375M to $385M, 75-80% YoY increase.","FIRDAPSE net product revenue guided $245M-$255M, up 17% vs. 2022.","FYCOMPA net product revenue forecast at ~$130M for 11 months after Jan. 24 acquisition.","Non-GAAP net income forecast of $195M to $205M for full-year 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3832360635.0606647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-06-01T23:59:59+00:00|294326"}